Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study

Background: Previous findings on using Glucagon-like peptide-1 receptor agonist (GLP1-RA) as an antidepressant were conflicting, lacking large-scale studies. We used population-based data to investigate depression and anxiety risk in diabetic patients receiving the medication. Methods: From claims r...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Wen-Hsuan, Sung, Fung-Chang, Chiu, Lu-Ting, Shih, Ying-Hsiu, Tsai, Ming-Chieh, Wu, Shu-I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904427/
https://www.ncbi.nlm.nih.gov/pubmed/35281896
http://dx.doi.org/10.3389/fphar.2022.765446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904427/
https://www.ncbi.nlm.nih.gov/pubmed/35281896
http://dx.doi.org/10.3389/fphar.2022.765446

Ejemplares similares